Cell therapy · Kills target cells, directed at DSG3 autoantibodies · developed by Cabaletta Bio
DSG3-CAART is an autologous T-cell therapy engineered to express a chimeric autoantibody receptor containing desmoglein-3 fused to 4-1BB and CD3zeta signaling domains. It targets and kills B-cells producing DSG3 autoantibodies, reducing autoantibody production in mucosal-dominant pemphigus vulgaris.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04422912 | Phase 1/2 | Pemphigus Vulgaris | Recruiting | CABA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Pemphigus Vulgaris
Updated Oct 3, 2026. Something wrong or missing? Report it on the CABA page.
See CABA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CABA catalysts and pipeline →